- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.95 Å
- Oligo State
- homo-octamer
- Ligands
- 8 x RLK: 2-azanyl-~{N}-[2-bromanyl-5-[4-[3-(dimethylamino)propylsulfonyl]piperazin-1-yl]phenyl]-1,3-oxazole-4-carboxamide(Non-covalent)
- 8 x OK8: (2~{S})-2-[[5-azanyl-1-[(2~{R},3~{R},4~{S},5~{R})-3,4-bis(oxidanyl)-5-(phosphonooxymethyl)oxolan-2-yl]imidazol-4-yl]car bonylamino]butanedioic acid(Non-covalent)
OK8.2: 18 residues within 4Å:- Chain A: T.40, A.41, G.42, E.97, V.99, R.101, T.105, G.106, S.107, D.189, M.190, K.191, D.212, S.213, W.214, R.215, K.228, R.232
18 PLIP interactions:18 interactions with chain A- Hydrogen bonds: A:T.40, A:G.42, A:S.107, A:S.107, A:F.108, A:D.189, A:D.212, A:D.212, A:K.228, A:R.232, A:R.232
- Salt bridges: A:K.17, A:K.17, A:R.101, A:R.215, A:K.228, A:K.228, A:R.232
OK8.4: 17 residues within 4Å:- Chain B: K.17, T.40, A.41, G.42, E.97, R.101, G.106, S.107, D.189, M.190, K.191, D.212, S.213, W.214, R.215, K.228, R.232
13 PLIP interactions:13 interactions with chain B- Hydrogen bonds: B:T.40, B:G.42, B:G.42, B:S.107, B:D.189, B:R.232
- Salt bridges: B:K.17, B:R.101, B:R.215, B:K.228, B:K.228, B:R.232
- pi-Cation interactions: B:K.191
OK8.6: 18 residues within 4Å:- Chain C: T.40, A.41, G.42, E.97, V.99, R.101, T.105, G.106, S.107, D.189, M.190, K.191, D.212, S.213, W.214, R.215, K.228, R.232
18 PLIP interactions:18 interactions with chain C- Hydrogen bonds: C:T.40, C:G.42, C:S.107, C:S.107, C:F.108, C:D.189, C:D.212, C:D.212, C:K.228, C:R.232, C:R.232
- Salt bridges: C:K.17, C:K.17, C:R.101, C:R.215, C:K.228, C:K.228, C:R.232
OK8.8: 17 residues within 4Å:- Chain D: K.17, T.40, A.41, G.42, E.97, R.101, G.106, S.107, D.189, M.190, K.191, D.212, S.213, W.214, R.215, K.228, R.232
13 PLIP interactions:13 interactions with chain D- Hydrogen bonds: D:T.40, D:G.42, D:G.42, D:S.107, D:D.189, D:R.232
- Salt bridges: D:K.17, D:R.101, D:R.215, D:K.228, D:K.228, D:R.232
- pi-Cation interactions: D:K.191
OK8.10: 18 residues within 4Å:- Chain E: T.40, A.41, G.42, E.97, V.99, R.101, T.105, G.106, S.107, D.189, M.190, K.191, D.212, S.213, W.214, R.215, K.228, R.232
18 PLIP interactions:18 interactions with chain E- Hydrogen bonds: E:T.40, E:G.42, E:S.107, E:S.107, E:F.108, E:D.189, E:D.189, E:D.212, E:K.228, E:R.232, E:R.232
- Salt bridges: E:K.17, E:K.17, E:R.101, E:R.215, E:K.228, E:K.228, E:R.232
OK8.12: 17 residues within 4Å:- Chain F: K.17, T.40, A.41, G.42, E.97, R.101, G.106, S.107, D.189, M.190, K.191, D.212, S.213, W.214, R.215, K.228, R.232
12 PLIP interactions:12 interactions with chain F- Hydrogen bonds: F:G.42, F:G.42, F:S.107, F:D.189, F:R.232
- Salt bridges: F:K.17, F:R.101, F:R.215, F:K.228, F:K.228, F:R.232
- pi-Cation interactions: F:K.191
OK8.14: 18 residues within 4Å:- Chain G: T.40, A.41, G.42, E.97, V.99, R.101, T.105, G.106, S.107, D.189, M.190, K.191, D.212, S.213, W.214, R.215, K.228, R.232
18 PLIP interactions:18 interactions with chain G- Hydrogen bonds: G:T.40, G:G.42, G:S.107, G:S.107, G:F.108, G:D.189, G:D.189, G:D.212, G:K.228, G:R.232, G:R.232
- Salt bridges: G:K.17, G:K.17, G:R.101, G:R.215, G:K.228, G:K.228, G:R.232
OK8.16: 17 residues within 4Å:- Chain H: K.17, T.40, A.41, G.42, E.97, R.101, G.106, S.107, D.189, M.190, K.191, D.212, S.213, W.214, R.215, K.228, R.232
12 PLIP interactions:12 interactions with chain H- Hydrogen bonds: H:G.42, H:G.42, H:S.107, H:D.189, H:R.232
- Salt bridges: H:K.17, H:R.101, H:R.215, H:K.228, H:K.228, H:R.232
- pi-Cation interactions: H:K.191
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Marttila, P. et al., Cellular and biochemical validation of a potent PAICS inhibitor. To Be Published
- Release Date
- 2022-04-20
- Peptides
- Multifunctional protein ADE2: ABCDEFGH
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
AD
BE
AF
BG
AH
B
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.95 Å
- Oligo State
- homo-octamer
- Ligands
- 8 x RLK: 2-azanyl-~{N}-[2-bromanyl-5-[4-[3-(dimethylamino)propylsulfonyl]piperazin-1-yl]phenyl]-1,3-oxazole-4-carboxamide(Non-covalent)
- 8 x OK8: (2~{S})-2-[[5-azanyl-1-[(2~{R},3~{R},4~{S},5~{R})-3,4-bis(oxidanyl)-5-(phosphonooxymethyl)oxolan-2-yl]imidazol-4-yl]car bonylamino]butanedioic acid(Non-covalent)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Marttila, P. et al., Cellular and biochemical validation of a potent PAICS inhibitor. To Be Published
- Release Date
- 2022-04-20
- Peptides
- Multifunctional protein ADE2: ABCDEFGH
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
AD
BE
AF
BG
AH
B